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In 1994, it was suggested that AGG interruptions affect the stability of the fragile X triplet
repeat. Until recently, however, this hypothesis was not explored on a large scale due
primarily to the technical difﬁculty of determining AGG interruption patterns of the two
alleles in females. The recent development of a PCR technology that overcomes this
difﬁculty and accurately identiﬁes the number and position of AGGs has led to several
studies that examine their inﬂuence on repeat stability. Here, we present a historical
perspective of relevant studies published during the last 20 years on AGG interruptions and
examine those recent publications that have reﬁned risk estimates for repeat instability
and full-mutation expansions.
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INTRODUCTION
Triplet repeat expansions in the 5′ untranslated region of the
fragile X gene (FMR1) are pathogenic and result in a spec-
trum of phenotypes, the most well characterized of which is
fragile X syndrome (FXS; OMIM #300624, Online Mendelian
Inheritance in Man, 2013a). Clinical phenotypes associated with
the fragile X premutation span cognitive, behavioral, mood,
reproductive, and motor dysfunctions, and include two recog-
nized conditions: fragile X-associated tremor/ataxia syndrome
(FXTAS; OMIM #300623, Online Mendelian Inheritance in Man,
2013b) and fragile X-associated primary ovarian insufﬁciency
(FXPOI; OMIM #300624, Online Mendelian Inheritance in Man,
2013a). The complexity of FMR1-associated clinical presenta-
tion reﬂects the toxicity of the expanded repeat and the critical
role of the protein product, fragile X mental retardation pro-
tein (FMRP). FMRP is a selective RNA-binding protein that
recognizes deﬁned sequence elements and structures (Darnell
et al., 2001, 2011; Ascano et al., 2012) and regulates translational
output. FMRP can bind to hundreds of different transcripts
to exert translational control. However, its selective regula-
tion of dendritic mRNAs in the brain that are implicated in
autism spectrum disorders (ASD) both underlies the frequent
diagnosis of ASD in FXS patients and provides a common
molecular pathology to link diverse autism phenotypes (Iossi-
fov et al., 2012; Parikshak et al., 2013). In FXS, repeat expansion
to greater than 200 CGGs is accompanied by hypermethyla-
tion of the repeat region, which shuts down FMRP production
and results in a loss of translational regulation by FMRP. In
the premutation disorders such as FXTAS, the clinical etiol-
ogy is thought to be overexpression of FMR1 mRNA, leading
to RNA toxicity and often reductions in FMRP (Hagerman
and Hagerman, 2013). Repeat-associated non-AUG translation
of FMR1 mRNA may also contribute to FXTAS (Todd et al.,
2013).
FRAGILE X REPEAT INSTABILITY
The mechanism of fragile X repeat expansion is not well under-
stood, but instability in both mitosis and meiosis is apparent.
Mitotic instability is reﬂected by somatic cell heterogeneity in the
number of CGG repeats. Studies that have analyzed sizemosaicism
in peripheral blood from full-mutation males have demonstrated
premutation mosaicism in > 40% of patients (Nolin et al., 1994),
and repeat number heterogeneity is evident in distinct tissues from
the same individual (Dobkin et al., 1996; Maddalena et al., 1996;
MacKenzie et al., 2006).
Meiotic repeat instability is implicated from the observed
CGG size difference between parents and children (Nolin et al.,
1996), and the variance in repeat numbers in individual sperm
cells and lymphocytes in male premutation carriers (Nolin et al.,
1999). The speciﬁc molecular timing of repeat expansion is unre-
solved, yet several studies indicate that transmission instability
manifests very early in development. Full-mutation, but not pre-
mutation, alleles are detected in the ovaries of full-mutation
fetuses, suggesting that maternal expansions do not occur purely
mitotically in the early embryo from an inherited premutation.
In contrast, the testes of a 13-week, but not a 17-week, full-
mutation fetus failed to show premutations in the germ cells
(Malter et al., 1997) but only premutation alleles are were detected
in the sperm of full-mutation males (Reyniers et al., 1993). Since
males and females can have categorically distinct fates after trans-
mission, differences in gametogenesis likely contribute to the
observed differences in repeat instability from parent to child.
Although it is currently unclear how errors in DNA replication
(Gerhardt et al., 2014) or repair (Lokanga et al., 2014) may con-
tribute to repeat expansion, cis sequence elements can inﬂuence
the process. The best characterized of these sequence elements
is the trinucleotide AGG, which commonly interrupts the CGG
repeat tract in normal individuals but has a reduced frequency in
carriers.
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AGG INTERRUPTIONS: INCIDENCE, STRUCTURAL
IMPLICATIONS, AND DETECTION METHODS
InterruptingAGG sequences were ﬁrst described in the early 1990s
(Eichler et al., 1994). Such interruptions are typically located at the
5′ end of the repeat tract, and are usually arrayedwith a periodicity
of 9–10 CGG repeats. Approximately 95% of normal individuals
have one or two AGG interruptions. Those with a family history
of FXS, however, often lack AGGs (Falik-Zaccai et al., 1997).
The low AGG density in longer alleles suggests a role in repeat
expansion. Biophysical studies have revealed distinct structures
for uninterrupted CGG sequences compared to those with AGG
interspersions. For example, oligodeoxynucleotides composed of
up to 39 pure CGG repeats form highly stable, stem–loop struc-
tures. These hairpins are destabilized by AGG sequences, and
different numbers of AGG sequences give rise to distinct con-
formations (Jarem et al., 2010). As these structures are thought
to be key intermediates in trinucleotide instability, it may be
that AGG sequences perturb CGG-speciﬁc, non B-DNA con-
ﬁgurations and thus engage a “biological brake” that curbs
expansion.
The idea that non-repeat elements can inﬂuence expansion
risk was suggested soon after the pathogenic FMR1 region was
identiﬁed (Fu et al., 1991; Snow et al., 1993). Eichler et al. (1994)
was the ﬁrst to present evidence that AGG interrupts can reduce
the probability of expansion during transmissions from parent to
child. A crucial ﬁnding from this study was the identiﬁcation of
an “instability threshold”of 34–38 uninterrupted CGG repeats. In
themiddle to late 1990s, additional studies proﬁled theAGG struc-
ture in both normal and premutation males, and demonstrated:
(1) AGG localization to the 5′ repeat segment; (2) CGG sequence
variation in the 3′ region; and (3) an increased frequency of unin-
terrupted CGG stretches in longer sequences (Kunst and Warren,
1994; Zhong et al., 1996).
Until recently, methods to reliably and efﬁciently interrogate
AGG structures from large study cohorts were elusive. Chen et al.
(2010) described an accurate PCR-based methodology capable
of deducing the AGG interruption pattern in both males and
females. This technology resolved the longstanding challenge of
untangling signal proﬁles from multiple, often overlapping, AGG
sequences. The assay reports distinct amplicon peaks for each
repeat length combination and identiﬁes AGG sequences from
characteristic signal losses in the repeat primed CGG trace (“AGG
dips”). With capabilities for low DNA inputs, quantitative sizing,
single repeat resolution, and a high-throughput workﬂow, this
technology became the method of choice to determine the impact
of AGGs upon different facets of FMR1 biology. The most con-
spicuous use of this PCR approach has been to assess AGG and
CGG genotypes in large study cohorts of allele transmissions from
parent to child.
REFINING THE RISK OF CGG REPEAT EXPANSION WITH AGG
INTERRUPTION INFORMATION
Although early studies suggested that repeat expansion was
unlikely below a threshold of 50–60 CGGs, it was a mystery
why some relatively small expansions were transmitted as full
mutations and other larger expansions were stably transmit-
ted. Consequently, expansions were binned into four categories:
normal (<45 CGG), intermediate or “gray zone” (45–54 CGG),
premutation (55–200 CGG), and full mutation (>200 CGG).
These categories were biased by our knowledge of FXS at the
time and by our early understanding of expansion risk, which
was thought to be limited to those with longer repeats. The
more recent emergence of distinct fragile X premutation disor-
ders with a broad spectrum of clinical involvement challenges
the ostensible solidity and utility of these longstanding categor-
ical boundaries (Hagerman and Hagerman, 2013). In addition,
knowledge gained from AGG mapping studies can now begin to
address ambiguities in allele stability that motivated a formal dec-
laration of uncertainty in the so-called“gray zone”or intermediate
category.
As an understanding of transmission instability came into
focus, several groups sought more accurate measures of expan-
sion risk (Figure 1). Studies published in the early 1990s evaluated
intergenerational stability in families with and without a his-
tory of fragile X, and the ﬁndings sketched the rough contours
of repeat-size determinants (Fu et al., 1991; Snow et al., 1993).
Speciﬁcally, alleles with < 40 CGGs rarely expanded, alleles with
40–54 CGGs occasionally expanded, and alleles with >54 CGGs
commonly expanded—some by hundreds of repeats, causing
FXS. These initial reports were extended by Nolin et al. (1996)
who assessed the repeat status of 191 families with fragile X
and an additional 33 families with gray zone repeats (deﬁned
as 40–60 repeats at the time). This study described improved
risk statistics for expansion of premutation alleles to full muta-
tions, and for the instability of shorter repeats that did not
expand to full mutations. A subsequent study (Nolin et al., 2003)
provided updated risk estimates using sample sets and anal-
ysis methods that corrected for ascertainment bias. Although
the smallest allele that expanded to a full mutation in this
cohort was 59 repeats, the overall risk of expansion for alle-
les with 55–59 CGGs was estimated to be only 1.1–3.7%. By
comparison, the full-mutation risk was about 10-fold higher
for mothers with 70–79 CGGs, and near 100% for mothers
with >100 CGGs. These results (particularly Table 1 of Nolin
et al., 2003) served as the basis for more informed genetic coun-
seling of at-risk families for the next decade (Finucane et al.,
2012).
A follow-up study of 1112 prenatal samples offered an unbiased
cohort that was even more well powered to assess expansion risk
as a function of repeat size (Nolin et al., 2011). Overall, the results
corroborated previous ﬁndings. The study also highlighted the
greater risk of families with a history of FXS. For example, 54%
of 70–79 CGG alleles from mothers with a family history of FXS
expanded to full mutations compared to only 11%with no history.
These data pointed to other genetic determinants that inﬂuence
full-mutation expansions, and AGG interruptions were a leading
candidate.
Although these three foundational risk studies (Nolin et al.,
1996, 2011, 2003) appraised the impact of total repeat length on
transmission instability, each also commented on the potential
stabilizing role for AGG interruptions. AGGmapping PCR (Chen
et al., 2010) was ﬁrst utilized in the 2011 Nolin study, and sub-
sequently in a study by Yrigollen et al. (2012) that described a
retrospective analysis of AGG interruptions in 267 premutation
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FIGURE 1 |Timeline for molecular advances and clinical impact of AGG
interruptions in the triplet repeat region of the FMR1 gene.The ﬁgure
identiﬁes several of the seminal publications in both basic and clinical research
that drove progress in our understanding of the role of AGG interruptions in
FMR1 triplet repeat expansions. Also shown are some of the key professional
guideline recommendations and committee opinions relevant to fragile X.
alleles representing 373 transmissions. As expected,AGG elements
substantially impacted the risk of a full-mutation expansion from
a given repeat length. For example, the risk varied by 10-fold
for 0 (49.6%) versus 2 (4%) AGG at 70 total repeats. Addi-
tional factors, such as ﬂanking haplotype markers or maternal
age, failed to show statistical signiﬁcance. The authors noted lim-
itations in the size of the cohort and bias in the population tested,
emphasizing the importance of further studies. In addition, the
most common repeats in the general population—smaller pre-
mutation and intermediate alleles—were not well characterized
in this study. Evidence-based risk measures were needed that
could help reassure the large fraction of at-risk individuals in this
range.
Consequently, Nolin et al. (2013) evaluated AGG interruptions
in 457 maternal and 81 paternal transmissions from parents with
45–69 repeats; this repeat range captures 95% of all interme-
diate and premutation alleles in the population (Seltzer et al.,
2012). Unlike Yrigollen et al. (2012), most of the samples were
drawn from population screening in this new study. The authors
demonstrated that AGG sequences strongly modulated the risk
of allele instability: 100/103 of alleles without AGGs were unsta-
ble (deﬁned as ≥1 repeat change) compared to 31/159 with 2
AGGs. Remarkably, alleles with 55–59 total repeats but 0–2 AGGs
spanned a 19-fold change in instability risk. Consistent with this
observation, all 9 of the observed cases of full-mutation expan-
sions in this cohort lacked AGGs. Furthermore, the magnitude
of repeat change correlated with the AGG status. The median
repeat number change for alleles with 0 AGGs compared to
those with 2 AGGs differed by as much as 10-fold (for 65–69
CGGs). Finally, the study demonstrated the greater instabil-
ity of paternal (81%) compared to maternal (47%) alleles, in
agreement with previous reports (Sullivan et al., 2002; Nolin
et al., 2011). Loss of AGGs, one plausible mechanism for insta-
bility, occurred in a single case, suggesting that this is a rare
event.
The seminal publications by Yrigollen et al. (2012) and Nolin
et al. (2013) also highlight the challenges in incorporating AGG
information into a single mathematical model that can guide
patient counseling—arguably the most important practical appli-
cation of these works. The two studies assessed distinct patient
populations, allele distributions, instability measures, and statis-
tical models. Any one of these factors can inﬂuence how AGG
information is incorporated into a cohesive risk model. Yrigollen
et al. (2012) utilized logistic regression and modeling using the
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Akaike Information Criterion (AIC), which favors goodness of
ﬁt with the fewest number of covariables. Nolin et al. (2013)
also invoked logistic regression and considered multiple predic-
tor variables, but further used linear regression and ANOVA to
assess the magnitude of instability. Both studies identiﬁed small
differences among the best models that considered various com-
binations of the AGG number, total repeat length, and the 3′
uninterrupted repeat length. Additional data are needed to reﬁne
thesemodels. Nevertheless, it is clear from these two studies, which
together represent >900 transmission events, that AGG informa-
tion can signiﬁcantly improve risk estimates for individuals with
intermediate and premutation alleles. These publications repre-
sent practical outcomes from 20 years of research into the role
of AGGs in repeat expansion (Figure 1), with opportunities to
improve genetic counseling and support a broader adoption of
fragile X screening.
IMPLICATIONS OF AGG GENOTYPING IN PATIENT TESTING
AND COUNSELING
Themounting evidence from recent risk studies invites discussion
for how AGG genotypes may be best incorporated into clinical
practice. This discussion, in turn, must consider recent trends
in fragile X screening. For example, the American Congress of
Obstetricians andGynecologists (ACOG,2010) on fragile X carrier
screening updated recommendations in 2010 to include women
who request screening rather than only those with a fragile X
family history. These changes tacitly acknowledge the rapid growth
in fragile X carrier screening, as has also been observed for many
other genetic disorders. As a result of this trend, we can expect
that far greater numbers of women with expanded alleles will be
identiﬁed in the future.
Large-scale increases in carrier detection present a greater pub-
lic health need for more informed risk assessment and counseling.
The 2013 update to the American College of Medical Genetics
(Monaghan et al., 2013) Standards and Guidelines for fragile X
testing noted the potential for AGG information to predict expan-
sion risk frompremutations with<100 repeats and the availability
of direct testing for these sequences (Figure 1). However, further
study was recommended to determine the clinical usefulness of
this testing. These guidelines were ﬁnalized with the insight of the
Yrigollen et al. (2012) study, but prior to the Nolin et al. (2013)
publication. Similarly, the National Society for Genetic Coun-
selors (NSGC) published a revision of practice guidelines in late
2012 (Finucane et al., 2012). Among the updates were recognition
of increased carrier screening forwomenwithout fragile X risk fac-
tors, and the availability of new PCR assays that can help resolve
the impact of AGGs in modeling expansion risk. These guidelines
also stressed the need to study the impact of AGG information in
genetic counseling practice.
The proﬁle of patients that may pursue AGG testing in the
future reﬂects both established high-risk groups and individuals
identiﬁed by screening. Historically, the assessment of expansion
risk has been driven by evidence of family history (including
unspeciﬁed intellectual disability or ASD) and/or females with
ovarian insufﬁciency. The vast majority of the estimated one
million carriers in the US are thus undiagnosed. Several trends,
however, are increasing the number of identiﬁed carriers. First,
carrier screening by academic laboratories and commercial enti-
ties using large panels of genes are rapidly gaining momentum.
Second, women are increasingly delaying family planning into
their third and fourth decades, which elevates the risk of com-
plications and often triggers additional high-complexity testing,
including genetic testing. Third, fragile X newborn screen-
ing pilot studies have identiﬁed individuals with intermediate
and premutation alleles; some of these individuals have then
been further analyzed using AGG genotyping (Yrigollen et al.,
2013).
Themajority of those identiﬁed with expanded alleles will have
intermediate or small premutation alleles with a low a priori risk
for a child with FXS. AGG testing is expected to provide reassur-
ance to those with AGG interruptions while alerting those with
the highest risk for instability. In clinical scenarios such as inva-
sive prenatal testing or assisted reproductive technologies, AGG
testing may assist in patient decision-making and medical man-
agement. Yet it is well known that other factors besides maternal
CGG repeat length and AGG interruptions contribute to the risk
of full-mutation expansions (Nolin et al., 2013). The presence of
AGGs, though reassuring, does not eliminate this risk altogether.
In addition, given that fragile X premutation carriers can have
normal phenotypes or a variable collection of clinical and sub-
clinical ﬁndings, some of which do not present until adulthood,
we anticipate that genetic counseling challenges will arise from the
growingnumber of women identiﬁedwithmodest expansions (for
example, 50–54 CGGs) and a quantiﬁable risk for transmitting a
premutation to their offspring.
FINAL PERSPECTIVES
Over the past two decades, our perception of AGG interruptions
has matured from a sequence curiosity to an established stability
factor that can help individualize the expansion risk for fragile X
carriers. Still, many questions remain at the level of basic and
clinical research as well as genetic counseling. How do AGGs
impact speciﬁc mechanisms of expansion? What effect do they
have on genotype–phenotype correlations across different clini-
cal presentations? How should parents be counseled, particularly
when their child has a risk to develop a premutation condition?
AndhowdoesAGG information affect decisionmaking bypatients
following counseling? These questions each require further
study.
The categories initially established for CGG repeat number
reﬂect an understanding of fragile X that has now advanced
to recognize clinical presentations beyond canonical FXS. How-
ever, our knowledge of the phenotypic spectrum across the full
range of CGG repeats is far from complete. Accurate repeat
length determination and improved methods for AGG geno-
typing may inﬂuence broader fragile X testing, and help clarify
links to phenotype. Instead of relying on normal, intermedi-
ate, and premutation allele categories, genetic counselors may
incorporate risk factors for expansion into a continuum calcu-
lated from repeat length and AGG status. As additional studies
seek answers and redeﬁne the fragile X phenotypic spectrum,
there is an emerging role for AGG genotyping to clarify the
course of fragile X genetic diagnosis, counseling, and patient
management.
Frontiers in Genetics | Genetic Disorders July 2014 | Volume 5 | Article 244 | 4
Latham et al. AGG interruptions in fragile X
ACKNOWLEDGMENTS
The authors thank the families whose supportmade this work pos-
sible. We also thank our many scientiﬁc colleagues over the years
that have contributed to the critical studies that have advanced
this ﬁeld. This work was supported in part by the New York State
Institute for Basic Research in Developmental Disabilities and the
New York State Ofﬁce of People with Developmental Disabilities,
and by the National Institutes of Health under Award Number
R44HD066953 (Asuragen). The content is solely the responsibil-
ity of the authors and does not necessarily represent the ofﬁcial
views of the National Institutes of Health.
REFERENCES
American Congress of Obstetricians and Gynecologists [ACOG]. (2010). Commit-
tee opinion No. 469 carrier screening for fragile X syndrome. Obstet. Gynecol.
116, 1008–1010. doi: 10.1097/AOG.0b013e3181fae884
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J. B., Nusbaum, J. D., Corcoran,
D. L., et al. (2012). FMRP targets distinct mRNA sequence elements to regulate
protein expression. Nature 492, 382–386. doi: 10.1038/nature11737
Chen, L., Hadd, A., Sah, S., Filipovic-Sadic, S., Krosting, J., Sekinger, E., et al.
(2010). An information-rich CGG repeat primed PCR that detects the full range
of fragile X expanded alleles and minimizes the need for southern blot analysis.
J. Mol. Diagn. 12, 589–600. doi: 10.2353/jmoldx.2010.090227
Darnell, J. C., Jensen, K. B., Jin, P., Brown, V., Warren, S. T., and Darnell, R. B.
(2001). Fragile X mental retardation protein targets G quartet mRNAs important
for neuronal function. Cell 107, 489–499. doi: 10.1016/S0092-8674(01)00566-9
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y., Mele, A., Fraser, C. E.,
et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic
function and autism. Cell 146, 247–261. doi: 10.1016/j.cell.2011.06.013
Dobkin, C. S., Nolin, S. L., Cohen, I., Sudhalter, V., Bialer, M. G., Ding, X. H.,
et al. (1996). Tissue differences in fragile Xmosaics: mosaicism in blood cells may
differ greatly from skin.Am. J.Med. Genet. 64, 296–301. doi: 10.1002/(SICI)1096-
8628(19960809)64:2<296::AID-AJMG13>3.0.CO;2-A
Eichler, E. E., Holden, J. J., Popovich, B. W., Reiss, A. L., Snow, K., Thibodeau, S. N.,
et al. (1994). Length of uninterrupted CGG repeats determines instability in the
FMR1 gene. Nat. Genet. 8, 88–94. doi: 10.1038/ng0994-88
Falik-Zaccai, T. C., Shachak, E., Yalon, M., Lis, Z., Borochowitz, Z., Macpherson,
J. N., et al. (1997). Predisposition to the fragile X syndrome in Jews of Tunisian
descent is due to the absence of AGG interruptions on a rare Mediterranean
haplotype. Am. J. Hum. Genet. 60, 103–112.
Finucane, B., Abrams, L., Cronister, A., Archibald, A. D., Bennett, R. L., and
Mcconkie-Rosell, A. (2012). Genetic counseling and testing for FMR1 genemuta-
tions: practice guidelines of the national society of genetic counselors. J. Genet.
Couns. 21, 752–760. doi: 10.1007/s10897-012-9524-8
Fu, Y. H., Kuhl, D. P., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S.,
et al. (1991). Variation of the CGG repeat at the fragile X site results in
genetic instability: resolution of the Sherman paradox. Cell 67, 1047–1058. doi:
10.1016/0092-8674(91)90283-5
Gerhardt, J., Tomishima, M. J., Zaninovic, N., Colak, D., Yan, Z., Zhan, Q., et al.
(2014). The DNA replication program is altered at the FMR1 locus in fragile X
embryonic stem cells. Mol. Cell 53, 19–31. doi: 10.1016/j.molcel.2013.10.029
Hagerman, R., and Hagerman, P. (2013). Advances in clinical and molecular
understanding of the FMR1 premutation and fragile X-associated tremor/ataxia
syndrome. Lancet Neurol. 12, 786–798. doi: 10.1016/S1474-4422(13)70125-X
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., et al.
(2012). De novo gene disruptions in children on the autistic spectrum. Neuron
74, 285–299. doi: 10.1016/j.neuron.2012.04.009
Jarem,D.A.,Huckaby, L.V., andDelaney, S. (2010). AGG interruptions in (CGG)(n)
DNA repeat tracts modulate the structure and thermodynamics of non-B
conformations in vitro. Biochemistry 49, 6826–6837. doi: 10.1021/bi1007782
Kunst, C. B., and Warren, S. T. (1994). Cryptic and polar variation of the frag-
ile X repeat could result in predisposing normal alleles. Cell 77, 853–861. doi:
10.1016/0092-8674(94)90134-1
Lokanga, R. A., Zhao, X. N., and Usdin, K. (2014). The mismatch repair protein
MSH2 is rate limiting for repeat expansion in a fragile X premutation mouse
model. Hum. Mutat. 35, 129–136. doi: 10.1002/humu.22464
MacKenzie, J. J., Sumargo, I., and Taylor, S. A. (2006). A cryptic full mutation
in a male with a classical fragile X phenotype. Clin. Genet. 70, 39–42. doi:
10.1111/j.1399-0004.2006.00634.x
Maddalena, A., Yadvish, K. N., Spence, W. C., and Howard-Peebles, P. N. (1996).
A fragile X mosaic male with a cryptic full mutation detected in epithelium
but not in blood. Am. J. Med. Genet. 64, 309–312. doi: 10.1002/(SICI)1096-
8628(19960809)64:2<309::AID-AJMG15>3.0.CO;2-J
Malter, H. E., Iber, J. C., Willemsen, R., De Graaff, E., Tarleton, J. C., Leisti, J., et al.
(1997). Characterization of the full fragile X syndromemutation in fetal gametes.
Nat. Genet. 15, 165–169. doi: 10.1038/ng0297-165
Monaghan K. G., Lyon E., Spector E. B. (2013). ACMG Standards and Guide-
lines for fragile X testing: a revision to the disease-speciﬁc supplements to the
Standards and Guidelines for Clinical Genetics Laboratories of the American
College of Medical Genetics and Genomics. Genet. Med. 15, 575–586. doi:
10.1038/gim.2013.61
Nolin, S. L., Brown, W. T., Glicksman, A., Houck, G. E. Jr., Gargano, A. D.,
Sullivan, A., et al. (2003). Expansion of the fragile X CGG repeat in females
with premutation or intermediate alleles. Am. J. Hum. Genet. 72, 454–464. doi:
10.1086/367713
Nolin, S. L., Glicksman, A., Ding, X., Ersalesi, N., Brown,W. T., Sherman, S. L., et al.
(2011). Fragile X analysis of 1112 prenatal samples from 1991 to 2010. Prenat.
Diagn. 31, 925–931. doi: 10.1002/pd.2815
Nolin, S. L., Glicksman, A., Houck, G. E. Jr., Brown, W. T., and Dobkin, C. S.
(1994). Mosaicism in fragile X affected males. Am. J. Med. Genet. 51, 509–512.
doi: 10.1002/ajmg.1320510444
Nolin, S. L., Houck, G. E. Jr., Gargano, A. D., Blumstein, H., Dobkin, C. S., and
Brown, W. T. (1999). FMR1 CGG-repeat instability in single sperm and lym-
phocytes of fragile-X premutation males. Am. J. Hum. Genet. 65, 680–688. doi:
10.1086/302543
Nolin, S. L., Lewis, F. A. III., Ye, L. L., Houck, G. E. Jr., Glicksman, A. E., et al.
(1996). Familial transmission of the FMR1 CGG repeat. Am. J. Hum. Genet. 59,
1252–1261.
Nolin, S. L., Sah, S., Glicksman, A., Sherman, S. L., Allen, E., Berry-Kravis, E., et al.
(2013). Fragile X AGG analysis provides new risk predictions for 45–69 repeat
alleles. Am. J. Med. Genet. A 161A, 771–778. doi: 10.1002/ajmg.a.35833
Online Mendelian Inheritance in Man, O. (2013a). MIM Number: #300624. Johns
Hopkins University, Baltimore, MD.
Online Mendelian Inheritance in Man, O. (2013b). MIM Number: #300623. Johns
Hopkins University, Baltimore, MD.
Parikshak, N. N., Luo, R., Zhang, A., Won, H., Lowe, J. K., Chandran, V., et al.
(2013). Integrative functional genomic analyses implicate speciﬁc molecular
pathways and circuits in autism. Cell 155, 1008–1021. doi: 10.1016/j.cell.2013.
10.031
Reyniers, E., Vits, L., De Boulle, K., Van Roy, B., Van Velzen, D., De Graaff, E., et al.
(1993). The full mutation in the FMR-1 gene of male fragile X patients is absent
in their sperm. Nat. Genet. 4, 143–146. doi: 10.1038/ng0693-143
Seltzer, M. M., Barker, E. T., Greenberg, J. S., Hong, J., Coe, C., and Almeida,
D. (2012). Differential sensitivity to life stress in FMR1 premutation carrier
mothers of children with fragile X syndrome. Health Psychol. 31, 612–622. doi:
10.1037/a0026528
Snow, K., Doud, L. K., Hagerman, R., Pergolizzi, R. G., Erster, S. H., and Thibodeau,
S. N. (1993). Analysis of a CGG sequence at the FMR-1 locus in fragile X families
and in the general population. Am. J. Hum. Genet. 53, 1217–1228.
Sullivan,A. K., Crawford, D. C., Scott, E. H., Leslie,M. L., and Sherman, S. L. (2002).
Paternally transmitted FMR1 alleles are less stable than maternally transmitted
alleles in the common and intermediate size range. Am. J. Hum. Genet. 70,
1532–1544. doi: 10.1086/340846
Todd, P. K., Oh, S. Y., Krans, A., He, F., Sellier, C., Frazer, M., et al. (2013).
CGG repeat-associated translation mediates neurodegeneration in fragile X
tremor ataxia syndrome. Neuron 78, 440–455. doi: 10.1016/j.neuron.2013.
03.026
Yrigollen, C. M., Durbin-Johnson, B., Gane, L., Nelson, D. L., Hagerman, R.,
Hagerman, P. J., et al. (2012). AGG interruptions within the maternal FMR1 gene
reduce the risk of offspring with fragile X syndrome. Genet. Med. 14, 729–736.
doi: 10.1038/gim.2012.34
Yrigollen, C. M., Mendoza-Morales, G., Hagerman, R., and Tassone, F. (2013).
Transmission of an FMR1 premutation allele in a large family identiﬁed through
newborn screening: the role of AGG interruptions. J. Hum. Genet. 58, 553–559.
doi: 10.1038/jhg.2013.50
www.frontiersin.org July 2014 | Volume 5 | Article 244 | 5
Latham et al. AGG interruptions in fragile X
Zhong, N., Ju, W., Pietrofesa, J., Wang, D., Dobkin, C., and Brown, W.T.
(1996). Fragile X “gray zone” alleles: AGG patterns, expansion risks, and
associated haplotypes. Am. J. Med. Genet. 64, 261–265. doi: 10.1002/(SICI)1096-
8628(19960809)64:2<261::AID-AJMG5>3.0.CO;2-X
Conflict of Interest Statement:G. Latham, J. Coppinger, andA.Hadd are employees
of Asuragen and own stock or stock options in the company. G. Latham is an
inventor on an issued US patent (8679757) that describes methods for detecting
AGG interruptions in the fragile X gene.
Received: 11 May 2014; accepted: 08 July 2014; published online: 29 July 2014.
Citation: Latham GJ, Coppinger J, Hadd AG and Nolin SL (2014) The role of AGG
interruptions in fragile X repeat expansions: a twenty-year perspective. Front. Genet.
5:244. doi: 10.3389/fgene.2014.00244
This article was submitted to Genetic Disorders, a section of the journal of Frontiers in
Genetics.
Copyright © 2014 Latham, Coppinger, Hadd and Nolin. This is an open-access article
distributed under the terms of the Creative CommonsAttribution License (CCBY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Genetics | Genetic Disorders July 2014 | Volume 5 | Article 244 | 6
